SCM
CTKB icon

Soleus Capital Management’s Cytek Biosciences CTKB Stock Holding History

Soleus Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-180,000
Closed -$1.94M – 74
2022
Q1 		$1.94M Buy
+180,000
New +$2.43M 0.25% 55

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Soleus Capital Management's CTKB Position: Q2 2022 in Review

Soleus Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2022, closing a stake of 180,000 shares — an estimated $1.94M sold.

Soleus Capital Management first reported a position in CTKB in Q1 2022 and held it in 1 quarter. The position peaked at $1.94M in Q1 2022. 84 funds tracked by Wall St. Rank hold CTKB as of Q2 2022.

  • Soleus Capital Management reported no remaining Cytek Biosciences position as of Q2 2022 after selling out during the quarter.
  • Soleus Capital Management sold 180,000 Cytek Biosciences shares in Q2 2022, an estimated $1.94M.
  • Soleus Capital Management first reported a position in Cytek Biosciences in Q1 2022 and held it in 1 quarter.
  • Soleus Capital Management's Cytek Biosciences position peaked at $1.94M in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2022.

Based on Soleus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.